Angion Biomedica Corp. (ANGN) Stock Analysis
NASDAQHealthcareBiotechnology
What Angion Biomedica Corp. does
Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs. The company's product pipeline also features ANG-3777, a hepatocyte growth factor mimetic engineered to treat acute organ injuries like delayed graft function, in addition to initiatives for ROCK2 inhibitors targeting fibrotic diseases and a CYP11B2 inhibitor program. Established in 1998, Angion Biomedica Corp. maintains its headquarters in Uniondale, New York.
Key metrics
ETFs linked to ANGN
Broad-market and Healthcare sector ETFs an investor holding Angion Biomedica Corp. is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how ANGN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze ANGN in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Angion Biomedica Corp.?
- Angion Biomedica Corp. trades under the ticker ANGN on NASDAQ.
- Which exchange is ANGN listed on?
- ANGN is listed on NASDAQ.
- What sector does Angion Biomedica Corp. operate in?
- Angion Biomedica Corp. is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze ANGN in a portfolio?
- PortView shows ANGN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.